GlaxoSmithKline Withdraws Application Seeking Patent for Antiretroviral Drug Combivir in India
August 23, 2006
GlaxoSmithKline withdrew a patent application in India for its twice-daily antiretroviral Combivir, Bloomberg/Philadelphia Inquirer reports. Although GSK did not give details as to why the application was withdrawn, N.Y. Sanglikar, spokesperson for the company's India unit, said in a telephone interview that it was withdrawn "voluntarily." Medecins Sans Frontieres in March said that groups in the country opposed the application because the drug was not new. The drug also would become more expensive because pharmaceutical companies that produce generic versions would have had to pay a "reasonable royalty" to the company, according to MSF (Bloomberg/Philadelphia Inquirer, 8/22).
Opponents of Male Circumcision Urge International Organizations Not to Back Procedure as HIV Prevention Strategy
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.